Expertise in
21
conditions

Dr. Michael A. Vogelbaum

Neurosurgery
Office
12902 Usf Magnolia Dr, 
Tampa, FL 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Expertise in
21
conditions
Office
12902 Usf Magnolia Dr, 
Tampa, FL 

Overview

Michael Vogelbaum is a Neurosurgery provider practicing medicine in Tampa, Florida.

Dr. Vogelbaum is highly rated in 21 conditions, according to our data. His clinical expertise encompasses Glioma, Brain Tumor, Gliomatosis Cerebri, Awake Craniotomy, and Gamma Knife Radiosurgery.

He is actively involved in clinical research, co-authoring 242 peer reviewed articles and participating in 10 clinical trials. Dr. Vogelbaum is currently accepting new patients.

Specialties

Neurosurgery

Licenses

Neurological Surgery in FL

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Florida Blue
  • EPO
  • PPO
Health Options
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Sunshine Health
  • EPO
  • HMO
View 2 Less Insurance Carriers -

Locations

Office
12902 Usf Magnolia Dr, Tampa, FL 33612

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

Phase I/II Study of Stereotactic Radiation and Abemaciclib in the Management of Hormone Receptor Positive HER2 Negative Breast Cancer Brain Metastases
Phase I/II Study of Stereotactic Radiation and Abemaciclib in the Management of Hormone Receptor Positive HER2 Negative Breast Cancer Brain Metastases
Enrollment Status: Recruiting
Publish Date: February 06, 2026
Intervention Type: Radiation, Drug
Study Drugs: Abemaciclib, Endocrine Therapy
Study Phase: Phase 1/Phase 2
A Safety Run-In and Phase II Study Evaluating the Efficacy, Safety, and Impact on the Tumor Microenvironment of the Combination of Tocilizumab, Atezolizumab, and Fractionated Stereotactic Radiotherapy in Recurrent Glioblastoma
A Safety Run-In and Phase II Study Evaluating the Efficacy, Safety, and Impact on the Tumor Microenvironment of the Combination of Tocilizumab, Atezolizumab, and Fractionated Stereotactic Radiotherapy in Recurrent Glioblastoma
Enrollment Status: Active_not_recruiting
Publish Date: August 27, 2026
Intervention Type: Procedure, Biological, Radiation
Study Drugs: Atezolizumab, Tocilizumab
Study Phase: Phase 2
Pre-operative Hypofractionated Stereotactic Radiosurgery for Resectable Brain Metastases
Pre-operative Hypofractionated Stereotactic Radiosurgery for Resectable Brain Metastases
Enrollment Status: Active_not_recruiting
Publish Date: March 31, 2026
Intervention Type: Radiation
Study Phase: Phase 2
A Pilot Study of Intratumorally and Intraparenchymally Administered OS2966 Using Convection-enhanced Delivery in Patients With Recurrent/Progressive High-grade Glioma Undergoing a Clinically-indicated Surgical Resection
A Pilot Study of Intratumorally and Intraparenchymally Administered OS2966 Using Convection-enhanced Delivery in Patients With Recurrent/Progressive High-grade Glioma Undergoing a Clinically-indicated Surgical Resection
Enrollment Status: Terminated
Publish Date: August 18, 2023
Intervention Type: Drug
Study Drugs: OS2966, Gadoteridol
Study Phase: Phase 1
A Study of Intratumorally-Administered Topotecan Using Convection-Enhanced Delivery (CED) in Patients With Suspected Recurrent/Progressive World Health Organization (WHO) Grade III or IV (High Grade) Glioma Undergoing Stereotactic Biopsy
A Study of Intratumorally-Administered Topotecan Using Convection-Enhanced Delivery (CED) in Patients With Suspected Recurrent/Progressive World Health Organization (WHO) Grade III or IV (High Grade) Glioma Undergoing Stereotactic Biopsy
Enrollment Status: Terminated
Publish Date: May 25, 2023
Intervention Type: Drug
Study Drug: Topotecan
Study Phase: Early Phase 1
An Open-Label Non-Randomized, Multi-Center Phase-2 Study of Convection-Enhanced Delivery (CED) of MDNA55 in Adults With Recurrent or Progressive Glioblastoma
An Open-Label Non-Randomized, Multi-Center Phase-2 Study of Convection-Enhanced Delivery (CED) of MDNA55 in Adults With Recurrent or Progressive Glioblastoma
Enrollment Status: Completed
Publish Date: October 24, 2022
Intervention Type: Drug
Study Phase: Phase 2
Clinical Study of the Utility of a Novel Exoscope System for 5-ALA Fluorescence-Guided Surgery for Gliomas
Clinical Study of the Utility of a Novel Exoscope System for 5-ALA Fluorescence-Guided Surgery for Gliomas
Enrollment Status: Completed
Publish Date: May 31, 2022
Intervention Type: Drug, Device
A Phase II, Multi-center, Open-label Study of a Conditionally Replicative Adenovirus (DNX-2401) With Pembrolizumab (KEYTRUDA®) for Recurrent Glioblastoma or Gliosarcoma (CAPTIVE/KEYNOTE-192)
A Phase II, Multi-center, Open-label Study of a Conditionally Replicative Adenovirus (DNX-2401) With Pembrolizumab (KEYTRUDA®) for Recurrent Glioblastoma or Gliosarcoma (CAPTIVE/KEYNOTE-192)
Enrollment Status: Completed
Publish Date: July 15, 2021
Intervention Type: Biological
Study Drugs: DNX-2401 Adeno-Associated Oncolytic Virus Delta-24 Vaccine, Pembrolizumab
Study Phase: Phase 2
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
Enrollment Status: Terminated
Publish Date: February 07, 2020
Intervention Type: Biological, Drug
Study Phase: Phase 2/Phase 3
Pilot Trial of Intratumorally-Administered Topotecan Using Convection-Enhanced Delivery (CED) in Patients With Suspected Recurrent/Progressive World Health Organization (WHO) Grade III or IV (High Grade) Glioma Undergoing Stereotactic Biopsy (IND 117,240)
Pilot Trial of Intratumorally-Administered Topotecan Using Convection-Enhanced Delivery (CED) in Patients With Suspected Recurrent/Progressive World Health Organization (WHO) Grade III or IV (High Grade) Glioma Undergoing Stereotactic Biopsy (IND 117,240)
Enrollment Status: Withdrawn
Publish Date: March 01, 2019
Intervention Type: Device, Drug, Diagnostic test
Study Phase: Early Phase 1
View 9 Less Clinical Trials

242 Total Publications

Prognostic and Predictive Effect of Age in Molecularly Defined Lower-Grade Gliomas.
Prognostic and Predictive Effect of Age in Molecularly Defined Lower-Grade Gliomas.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: August 12, 2026
Similar Doctors
Expertise in
25
conditions
Dr. Arnold B. Etame
Neurosurgery
Expertise in
25
conditions
Dr. Arnold B. Etame
Neurosurgery
Referral may be required

Moffitt Cancer Center, Magnolia Campus

12902 Usf Magnolia Dr, 
Tampa, FL 
 (0.1 miles away)
813-852-5275
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Arnold Etame is a Neurosurgery provider practicing medicine in Tampa, Florida. Dr. Etame is highly rated in 25 conditions, according to our data. His clinical expertise encompasses Brain Tumor, Glioblastoma, Astrocytoma, Awake Craniotomy, and Gamma Knife Radiosurgery. Dr. Etame is currently accepting new patients.

Expertise in
24
conditions
Dr. Siviero Agazzi
Neurosurgery
Expertise in
24
conditions
Dr. Siviero Agazzi
Neurosurgery
Referral may be required

Univ. Medical Service Association Inc.

13330 Usf Laurel Dr, 
Tampa, FL 
 (0.3 miles away)
813-974-2201
Languages Spoken:
English, French, German, Italian, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Siviero Agazzi is a Neurosurgery provider practicing medicine in Tampa, Florida. Dr. Agazzi is highly rated in 24 conditions, according to our data. His clinical expertise encompasses Acoustic Neuroma, Schwannoma, Meningioma, Extracranial-Intracranial Bypass Surgery, and Microvascular Decompression. Dr. Agazzi is currently accepting new patients.

Expertise in
16
conditions
Dr. Elad I. Levy
Neurosurgery
Expertise in
16
conditions
Dr. Elad I. Levy
Neurosurgery
Referral may be required

Sarasota Memorial Hospital-Sarasota

1700 S Tamiami Trl, 
Sarasota, FL 
 (51.9 miles away)
941-917-9000
Languages Spoken:
English
See accepted insurances

Elad Levy is a Neurosurgery provider practicing medicine in Sarasota, Florida. Dr. Levy is highly rated in 16 conditions, according to our data. His clinical expertise encompasses Brain Aneurysm, Stroke, Chronic Subdural Hematoma, Thrombectomy, and Stent Placement.

Frequently Asked Questions about Dr. Michael A. Vogelbaum

How do I make an appointment with Dr. Michael A. Vogelbaum?

You can book an appointment with Dr. Michael A. Vogelbaum by calling their office at 813-745-4673. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Michael A. Vogelbaum a top-rated expert for Glioma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Michael A. Vogelbaum is classified as an Elite expert for Glioma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Michael A. Vogelbaum specialize in?

While Dr. Michael A. Vogelbaum is a Neurosurgery, they have specific expertise in Glioma, Brain Tumor, and Gliomatosis Cerebri. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Neurosurgery.

Does Dr. Michael A. Vogelbaum participate in research or clinical trials?

Yes. Dr. Michael A. Vogelbaum has published 242 articles and abstracts on conditions like Glioma. You can view a list of Dr. Michael A. Vogelbaum's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Michael A. Vogelbaum accept my insurance?

Dr. Michael A. Vogelbaum accepts most major insurance plans, including Aetna and Blue Cross Blue Shield. We recommend calling the office directly at 813-745-4673 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Vogelbaum's expertise for a condition
ConditionClose
View All 7 Distinguished Conditions
View All 9 Advanced Conditions
View All 32 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile